Faes Farma SA banner
F

Faes Farma SA
MAD:FAE

Watchlist Manager
Faes Farma SA
MAD:FAE
Watchlist
Price: 4.76 EUR -0.63% Market Closed
Market Cap: €1.5B

EV/FCFF

31.8
Current
72%
More Expensive
vs 3-y average of 18.5

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
31.8
=
Enterprise Value
€1.7B
/
Free Cash Flow to Firm
€54.8m

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
31.8
=
Enterprise Value
€1.7B
/
Free Cash Flow to Firm
€54.8m

Valuation Scenarios

Faes Farma SA is trading above its 3-year average

If EV/FCFF returns to its 3-Year Average (18.5), the stock would be worth €2.77 (42% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-42%
Maximum Upside
+7%
Average Downside
27%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple 31.8 €4.76
0%
3-Year Average 18.5 €2.77
-42%
5-Year Average 21.5 €3.22
-32%
Industry Average 34.1 €5.11
+7%
Country Average 18.6 €2.78
-42%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
ES
Faes Farma SA
MAD:FAE
1.5B EUR 31.8 18.6
US
Eli Lilly and Co
NYSE:LLY
804.2B USD 140.4 39
US
Johnson & Johnson
NYSE:JNJ
547.4B USD 29.1 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 26.4 20.1
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 34.8 27.5
CH
Novartis AG
SIX:NOVN
220.1B CHF 19 19.5
US
Merck & Co Inc
NYSE:MRK
274.6B USD 24.8 15
IE
Endo International PLC
LSE:0Y5F
244.4B USD 1 486.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 42.2 11.1
US
Pfizer Inc
NYSE:PFE
150.6B USD 21.8 19.2
US
Bristol-Myers Squibb Co
NYSE:BMY
115.9B USD 11.6 16.4
P/E Multiple
Earnings Growth PEG
ES
F
Faes Farma SA
MAD:FAE
Average P/E: 21.2
18.6
16%
1.2
US
Eli Lilly and Co
NYSE:LLY
39
32%
1.2
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.5
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.2
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.4
16%
1

Market Distribution

Higher than 73% of companies in Spain
Percentile
73rd
Based on 567 companies
73rd percentile
31.8
Low
0 — 13
Typical Range
13 — 28.2
High
28.2 —
Distribution Statistics
Spain
Min 0
30th Percentile 13
Median 18.6
70th Percentile 28.2
Max 1 712.4

Faes Farma SA
Glance View

Faes Farma SA, a notable player in the pharmaceutical arena, has orchestrated its operations with the precision of a seasoned conductor. Rooted in Spain with an impressive international reach, the company blends research prowess with adept production capabilities. Central to its modus operandi is the development, manufacture, and commercialization of a wide range of pharmaceutical products and nutritional supplements. With science as its guiding star, Faes Farma dedicates substantial resources to research and development, ensuring a pipeline filled with innovative treatments that cater to diverse medical needs. The company has carved its niche by focusing on therapeutic areas such as allergy, dermatology, and the central nervous system, allowing it to create specialized solutions that resonate well with healthcare providers and patients alike. The company’s revenue engine is driven primarily by its robust product sales, enhanced by strategic partnerships and licensing agreements that bolster its market presence both in Spain and across global markets. Through rigorous production processes, Faes Farma ensures the delivery of high-quality medications, matching industry standards and fostering consumer trust. Additionally, its geographical diversification, with subsidiaries and distribution channels spreading across Europe, Latin America, and Africa, underpins its economic durability. By marrying innovation with strategic commercial tactics, Faes Farma has deftly navigated the complexities of the pharmaceutical landscape, ensuring not only profitability but also the sustained delivery of health-enhancing products to the global community.

FAE Intrinsic Value
2.9 EUR
Overvaluation 39%
Intrinsic Value
Price €4.76
F
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett